NCT Number: NCT05168618
Phase: Phase 2
Trial Summary: This phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the bod – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): University of Utah|National Cancer Institute (NCI)
Acronym:
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives